Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial)

Granados-Montiel et al., BMJ Open, doi:10.1136/bmjopen-2020-045190, ELEVATE, NCT04340349
Jun 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Estimated 214 participant HCQ + bromhexine prophylaxis RCT with results not reported over 2 years after estimated completion.
39 HCQ RCTs have results missing long after expected Abayomi, Abu-Helalah, Ajili, Akram, Al Ansari, Aston, Borrie, Burney, Butler, Chauffe, Connor, El-Sherbiny, Farooq, Gagneux-Brunon, Genton, Ghanem-Zoubi, González, Granados-Montiel, Gül, Hawari, James, Kara, Kim, Levi, Mežnar, Moraes, Morales-Asencio, Mordmüller, Nanni, Niriella, Okasha, Pellegrini, Pineda, Sarwar, Sarwar (B), Sow, Treluyer, WellStar, White
The trials report a total of 25,949 patients, with 13 trials having actual enrollment of 8,689, and the remainder estimated.
Study covers bromhexine and HCQ.
Granados-Montiel et al., 30 Jun 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Mexico, peer-reviewed, this trial uses multiple treatments in the treatment arm (combined with bromhexine) - results of individual treatments may vary, trial NCT04340349 (history) (ELEVATE). Contact:
This PaperHCQAll
New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial)
Dr Julio Granados-Montiel, Eric Hazan-Lasri, Rafael Franco-Cendejas, Tatiana Chávez-Heres, Phaedra Silva-Bermudez, Rocio Aguilar-Gaytán, Natalia Manzano-León, Karla Méndez-Maldonado, Alejandro Alvarez-Arce, Raigam Jafet Martínez-Portilla
BMJ Open, doi:10.1136/bmjopen-2020-045190
New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial).
Competing interests None declared. Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Patient consent for publication Not required. Ethics approval The approval of the research ethics committee of the INR-LGII of Mexico has been obtained. Provenance and peer review Not commissioned; externally peer reviewed. Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by-nc/ 4. 0/. ORCID iD Julio Granados-Montiel http:// orcid. org/ 0000-0002-0611-6421
22 Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2012410
Baig, Khaleeq, Ali, Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms, ACS Chem Neurosci, doi:10.1021/acschemneuro.0c00122
Chang, Sun, Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges, Drug Discov Today, doi:10.1016/j.drudis.2020.06.030
Chude, Amaravadi, Targeting autophagy in cancer: update on clinical trials and novel inhibitors, Int J Mol Sci, doi:10.3390/ijms18061279
Depfenhart, De Villiers, Lemperle, Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?, Intern Emerg Med, doi:10.1007/s11739-020-02383-3
Dm, COVID-19 dashboard México
Dutta, Sharma, Sharma, Short-Term hydroxychloroquine in COVID-19 infection in people with or without metabolic syndrome -clearing safety issues and good clinical practice, Eur Endocrinol, doi:10.17925/EE.2020.16.2.109
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Han, Ma, Li, Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors, Emerg Microbes Infect, doi:10.1080/22221751.2020.1770129
Helal, Gad, Mohamed Fahmy Abd-Ellah and Mse. hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in Genotype-4 chronic hepatitis C patients, Antivir Ther
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Juurlink, Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection, CMAJ, doi:10.1503/cmaj.200528
Lai, Yu, Wang, Shorter incubation period is associated with severe disease progression in patients with COVID-19, Virulence, doi:10.1080/21505594.2020.1836894
Levy, Yagil, Bursztyn, Ace2 expression and activity are enhanced during pregnancy, Am J Physiol Regul Integr Comp Physiol, doi:10.1152/ajpregu.90592.2008
Li, Wang, Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-Family cluster, Emerg Infect Dis, doi:10.3201/eid2607.200718
Luzzi, Peto, Adverse effects of antimalarials. An update, Drug Saf, doi:10.2165/00002018-199308040-00004
Mareev, Orlova, Pavlikova, Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT), Kardiologiia, doi:10.18087/cardio.2020.8.n1307
Paiardini, Müller-Trutwin, HIV-Associated chronic immune activation, Immunol Rev, doi:10.1111/imr.12079
Pal, Berhanu, Desalegn, Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): an update, Cureus, doi:10.7759/cureus.7423
Ravi, Cortade, Ng, Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape, Biosensors and Bioelectronics, doi:10.1016/j.bios.2020.112454
Remuzzi, Remuzzi, COVID-19 and Italy: what next?, Lancet, doi:10.1016/S0140-6736(20)30627-9
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wang, Lin, Huang, Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery, Journal of Interferon & Cytokine Research, doi:10.1089/jir.2014.0038
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China, JAMA, doi:10.1001/jama.2020.2648
Xu, Zhong, Deng, High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa, Int J Oral Sci, doi:10.1038/s41368-020-0074-x
Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
Zahr, Urien, Llopis, Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19, Therapie, doi:10.1016/j.therap.2021.01.056
Zanasi, Mazzolini, Kantar, A reappraisal of the mucoactive activity and clinical efficacy of bromhexine, Multidiscip Respir Med, doi:10.1186/s40248-017-0088-1
Zhan, Qin, Xue, Death from Covid-19 of 23 health care workers in China, N Engl J Med, doi:10.1056/NEJMc2005696
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop